8QYQ

Beta-cardiac myosin S1 fragment in the pre-powerstroke state complexed to Mavacamten

Summary for 8QYQ

• Entry DOI: 10.2210/pdb8qyq/pdb
• Descriptor: Myosin-7, Myosin light chain 3, ADENOSINE-5'-DIPHOSPHATE, ... (10 entities in total)
• Functional Keywords: cardiac myosin modulators inherited cardiomyopathies mavcamten, contractile protein
• Biological source: Bos taurus (cattle); More
• Total number of polymer chains: 4
• Total formula weight: 230505.56

Authors

Robert-Paganin, J.,Kikuti, C.,Auguin, D.,Rety, S.,David, A.,Houdusse, A. (deposition date: 2023-10-26, release date: 2023-12-13)

Primary citation

Auguin, D.,Robert-Paganin, J.,Rety, S.,Kikuti, C.,David, A.,Theumer, G.,Schmidt, A.W.,Knolker, H.J.,Houdusse, A.
Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite antagonistic effects in heart contraction.
Biorxiv, 2023

PubMed Abstract: Inherited cardiomyopathies are amongst the most common cardiac diseases worldwide, leading in the late-stage to heart failure and death. The most promising treatments against these diseases are small-molecules directly modulating the force produced by β-cardiac myosin, the molecular motor driving heart contraction. Two of these molecules that produce antagonistic effects on cardiac contractility have completed clinical phase 3 trials: the activator and the inhibitor . In this work, we reveal by X-ray crystallography that both drugs target the same pocket and stabilize a pre-stroke structural state, with only few local differences. All atoms molecular dynamics simulations reveal how these molecules can have antagonistic impact on the allostery of the motor by comparing β-cardiac myosin in the apo form or bound to or . Altogether, our results provide the framework for rational drug development for the purpose of personalized medicine.

PubMed: 38014327
DOI: 10.1101/2023.11.15.567213

Experimental method

X-RAY DIFFRACTION (2.61 Å)